UK Clinical Guidance GLP-1 receptor agonists are medications used to manage type 2 diabetes and support weight management, traditionally given by injection
This article draws on published Phase 2 trial data to explain what participants commonly experience and when to seek medical advice
Cardiometabolic improvements across published trials include reductions in blood pressure, triglycerides, LDL-cholesterol, HbA1c, and fasting glucose
Side effects are a concern, as with any other treatment
A well-established part of how they work is slowing gastric emptying, so food stays in the stomach longer, and this is documented in the FDA prescribing information for these drugs
Effects of glucagon-like peptide-1 on the differentiation and metabolism of human adipocytes